[ 메디채널 김갑성 기자 ] 500 family volunteers distribute over 10,000 free flags to encourage the public to share their feelings HONG KONG, Oct. 18, 2025 -- Manulife Hong Kong and JUST FEEL, a Hong Kong-based NGO dedicated to emotional education, successfully held the city's first-ever "My Flag Day" today. A total of 500 family volunteers from Manulife and nine of JUST FEEL's partner schools engaged with 10,000 citizens across the city, encouraging them to select a flag to wear, which would represent their current feelings. This initiative aims to raise public awareness of self-care
SUZHOU, China, Oct. 18, 2025 -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)) (Study ID: KN026-001, also known as KC-WISE), have been presented at the 2025 E
SINGAPORE, Oct. 18, 2025 -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I trial (NCT06544720) in patients with recurrent or metastatic HPV-associated carcinomas. The poster will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, on Saturday, 18 October 2025. This ongoing first-in-human trial evaluates the safety,
GUANGZHOU, China, Oct. 18, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
[ 메디채널 김갑성 기자 ] AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients with heavily pretreated EGFR Wild-type NSCLC and other advanced solid tumors without CD44v9 pre-selection SHANGHAI, Oct. 17, 2025 -- Multitude Therapeutics, Inc., a clinical-stage company focused on the development of antibody-drug-conjugate (ADC) drugs, today announced initial data from its ongoing phase I/II
NEW YORK, Oct. 17, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension Kristen Scholer delivers the pre-market update on October 17th Stocks are lower early Friday after regional bank reports created concerns over bad loans. Loose lending practices pushed traders into safe havens. Activity in the banking sector could infor
CHENGDU, China, Oct. 17, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have received one or more prior anti-HER2 therapy. The approval is based on a multi-center, randomized, open-label
GUANGZHOU, China, Oct. 17, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
GUANGZHOU, China, Oct. 17, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
The new tertiary hospital will be located within the NorthBank Township in Kuching, Sarawak and is targeted to launch in 2029 SINGAPORE, Oct. 17, 2025 -- Health Mangement International Pte Ltd ("HMI Medical") has signed a Memorandum of Agreement ("MoA") with KLSE listed and Sarawak-based property and infrastructure developer, Ibraco Berhad, ("Ibraco") for the acquisition of land for the construction of its third hospital in Malaysia. Fully owned and operated by HMI Medical, Regency Hospital Kuching, a new private specialist hospital will be located